The Consumer Healthcare Products Association (CHPA) today released the below statement following the U.S. Food and Drug Administration’s (FDA) public release of briefing materials
Millions of Americans rely on OTC medicines. Following the COVID-19 pandemic, OTCs have become an even more essential part of the treatment toolbox. Today, we take a look at the value created by OTC medicines as we walk through some of the top findings from CHPA's latest OTC value study.
CHPA applauds FDA for taking a critical step forward today in public health, which will remove many of the barriers and stigmas attached to this life-saving emergency therapy for opioid overdoses
CHPA released the below statement today following the U.S. Food and Drug Administration’s announcement that it will postpone its previously scheduled April 12 Nonprescription Drugs Advisory Committee meeting to reconsider the efficacy of oral phenylephrine.
Good science, and new customer behavior mean the time is right for companies to evaluate their portfolios to position themselves for success. Tailwinds are good, private equity interest is high, and the self-care future is bright.
CHPA tracks FDA progress vs. OMUFA goals and activities referenced in legislation. These goals were negotiated between the Agency and Industry prior to the legislation and cover the 5-year period for OMUFA I (October 1, 2020 – September 30, 2025).
